MSBio Expands into Singapore Market with 'AM Lens'

Regulatory procedures by Singapore's Health Sciences Authority (HSA) for MSBio's ophthalmic amniotic membrane product 'AM Lens' have been completed, making local supply possible.

According to MSBio on the 29th, local distribution will be handled by Singaporean pharmaceutical distributor Wellchem Pharmaceuticals Pte Ltd.

AM Lens is an ophthalmic product that implements a human amniotic membrane in the form of a contact lens. Unlike the conventional suture-based amniotic membrane application method, it is designed to be used without sutures. It features high transparency and pre-processed curvature, maximizing ease of use for healthcare professionals and applicability in clinical settings.

This entry into the Singaporean market is part of MSBio's strategy to expand its business in Southeast Asia. On September 11, the company signed a memorandum of understanding (MOU) with Dong Do Hospital and Dong Do Hospital Tissue Bank in Hanoi, Vietnam, to build local tissue bank operation capabilities and cooperate in supplying amniotic membrane products.

Given that supplying AM Lens locally is a key objective of the collaboration with Dong Do Hospital in Vietnam, MSBio plans to further expand its entry into the Southeast Asian ophthalmic market, focusing on Singapore and Vietnam.

Seongpo Kim, CEO of MSBio, stated, "By securing a supply base in Singapore, we plan to accelerate the entry of AM Lens into the Southeast Asian market," adding, "Starting with Singapore and Vietnam, we will continue to expand local partnerships and distribution networks to actively launch into the global ophthalmic market."

This content was produced with the assistance of AI translation services.